John L. Pulice

John L. Pulice

Auto-generated profile, based on publicly available information

John L. Pulice

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CKCigall Kadoch
Cigall Kadoch
RWRobert T Williams
Robert T Williams
JCJoseph P Calarco
Joseph P Calarco
EMErik L Miller
Erik L Miller
CWChristopher M Weber
Christopher M Weber
GCGerald R Crabtree
Gerald R Crabtree
Gerald Crabtree, Cigall Kadoch and colleagues report that BAF complexes oppose PRC by rapid, ATP-dependent eviction in the absence of Pol II occupancy, transcription or replication, leading to the formation of accessible chromatin. They also find that tumor-suppressor and oncogenic mutations in BAF subunits result in differential effects on PRC eviction. The opposition between Polycomb repressive complexes (PRCs) and BAF (mSWI/SNF) complexes has a critical role in both development and disease. Mutations in the genes encoding BAF subunits contribute to more than 20% of human malignancies, yet the underlying mechanisms remain unclear, owing largely to a lack of assays to assess BAF function in living cells. To address this, we have developed a widely applicable recruitment assay system through which we find that BAF opposes PRC by rapid, ATP-dependent eviction, leading to the formation of accessible chromatin. The reversal of this process results in reassembly of facultative heterochromatin. Surprisingly, BAF-mediated PRC eviction occurs in the absence of RNA polymerase II (Pol II) occupancy, transcription, and replication. Further, we find that tumor-suppressor and oncogenic mutant BAF complexes have different effects on PRC eviction. The results of these studies define a mechanistic sequence underlying the resolution and formation of facultative heterochromatin, and they demonstrate that BAF opposes PRC on a minute-by-minute basis to provide epigenetic plasticity.

25 September 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RNRobert T Nakayama
Robert T Nakayama
JPJohn L Pulice
John L Pulice
AVAlfredo M Valencia
Alfredo M Valencia
MMMatthew J McBride
Matthew J McBride
ZMZachary M McKenzie
Zachary M McKenzie
CKCigall Kadoch
Cigall Kadoch
Loss of BAF47 destabilizes the BAF complex on chromatin, and reintroduction of BAF47 leads to enhancer activation and Polycomb opposition at bivalent promoters. BAF47 loss affects BAF and PBAF complexes, which have distinct functions in regulation of enhancers and promoters. Perturbations to mammalian SWI/SNF (mSWI/SNF or BAF) complexes contribute to more than 20% of human cancers, with driving roles first identified in malignant rhabdoid tumor, an aggressive pediatric cancer characterized by biallelic inactivation of the core BAF complex subunit SMARCB1 (BAF47). However, the mechanism by which this alteration contributes to tumorigenesis remains poorly understood. We find that BAF47 loss destabilizes BAF complexes on chromatin, absent significant changes in complex assembly or integrity. Rescue of BAF47 in BAF47-deficient sarcoma cell lines results in increased genome-wide BAF complex occupancy, facilitating widespread enhancer activation and opposition of Polycomb-mediated repression at bivalent promoters. We demonstrate differential regulation by two distinct mSWI/SNF assemblies, BAF and PBAF complexes, enhancers and promoters, respectively, suggesting that each complex has distinct functions that are perturbed upon BAF47 loss. Our results demonstrate collaborative mechanisms of mSWI/SNF-mediated gene activation, identifying functions that are co-opted or abated to drive human cancers and developmental disorders.

1 June 2018 in Cancer Cell
Verified
Journal Article
Closed access
MMMatthew J. McBride
Matthew J. McBride
JPJohn L. Pulice
John L. Pulice
HBHannah Beird
Hannah Beird
DIDavis R. Ingram
Davis R. Ingram
ADAndrew R. D’aVino
Andrew R. D’aVino
CKCigall Kadoch
Cigall Kadoch

1 August 2018 in Molecular Cell
Verified
Journal Article
Closed access
GSGabriel J. Sandoval
Gabriel J. Sandoval
JPJohn L. Pulice
John L. Pulice
HPHubert Pakula
Hubert Pakula
MSMonica Schenone
Monica Schenone
DTDavid Y. Takeda
David Y. Takeda
CKCigall Kadoch
Cigall Kadoch

1 January 2016 in Cold Spring Harbor Symposia on Quantitative Biology
Verified
Journal Article
Open access
PDF file
JPJohn L. Pulice
John L. Pulice
CKCigall Kadoch
Cigall Kadoch
Mammalian SWI/SNF (BAF) chromatin remodeling complexes play critical roles in maintaining chromatin architecture and gene expression. Genomic sequencing efforts over the past several years have unveiled a major role for these complexes in the development of human cancer as well as neurologic disease, prompting the need to interrogate underlying mechanisms and to develop new methods to comprehensively understand mSWI/SNF complex function. Here we discuss the emerging insights from genetic, biochemical, and functional genomic studies in the field and suggest approaches toward further basic investigations, as well as therapeutic targeting of chromatin remodeling machinery.

21 August 2025 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
WLWeicheng Li
Weicheng Li
EGEnrique Garcia-Rivera
Enrique Garcia-Rivera
DMDylan C. Mitchell
Dylan C. Mitchell
JCJoel M. Chick
Joel M. Chick
MMMicah Maetani
Micah Maetani
JOJonathan M. L. Ostrem
Jonathan M. L. Ostrem
Ubiquitin is a small, highly conserved protein that acts as a posttranslational modification in eukaryotes. Ubiquitination of proteins frequently serves as a degradation signal, marking them for disposal by the proteasome. Here we report a novel small molecule from a diversity-oriented synthesis library, BRD1732, that is directly ubiquitinated in cells, resulting in dramatic accumulation of inactive ubiquitin monomers and polyubiquitin chains, which causes broad inhibition of the ubiquitin–proteasome system. Ubiquitination of BRD1732 and its associated cytotoxicity are stereospecific and dependent on two homologous E3 ubiquitin ligases, RNF19A and RNF19B, and their shared E2 conjugating enzyme, UBE2L3. Our finding opens the possibility for indirect ubiquitination of a target through a ubiquitinated bifunctional small molecule and more broadly raises the potential for posttranslational modification in trans .